Gossamer Bio (GOSS) Non Operating Income (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Non Operating Income of -$1.8 million for Q1 2026, down 1145.35% year-over-year from $172000.0 in Q1 2025, and down 39.7% quarter-over-quarter from -$1.3 million in Q4 2025.
Gossamer Bio (GOSS) Non Operating Income (2018 - 2026) Analysis & Trends
Gossamer Bio's Non Operating Income history runs 9 years deep, the most recent figure standing at -$1.8 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 1145.35% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at -$1.7 million (down 138.42% YoY), while the FY2025 annual figure was $270000.0, down 93.7% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1.8 million, down from -$1.3 million in the prior quarter.
- The five-year high for Non Operating Income was $3.8 million in Q2 2023, with the low at -$3.4 million in Q1 2022.
- The 5-year median for Non Operating Income is $172000.0 (2025), against an average of -$240411.8.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income jumped 454.84% in 2025, then sank 1145.35% in 2026.
- Gossamer Bio's Non Operating Income stood at -$1.4 million in 2022, then jumped by 162.47% to $879000.0 in 2023, then fell by 21.62% to $689000.0 in 2024, then sank by 286.79% to -$1.3 million in 2025, then tumbled by 39.7% to -$1.8 million in 2026.
- Business Quant data shows GOSS's Non Operating Income at -$1.8 million in Q1 2026, -$1.3 million in Q4 2025, and $893000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | 42.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.97 Mn |
| Mar 31, 2026 | -1.80 Mn |
| Dec 31, 2025 | -1.29 Mn |
| Sep 30, 2025 | 893,000.00 |
| Jun 30, 2025 | 492,000.00 |
| Mar 31, 2025 | 172,000.00 |
| Dec 31, 2024 | 689,000.00 |
| Sep 30, 2024 | 1.98 Mn |
| Jun 30, 2024 | 1.58 Mn |
| Mar 31, 2024 | 31,000.00 |
| Dec 31, 2023 | 879,000.00 |
| Sep 30, 2023 | 482,000.00 |
| Jun 30, 2023 | 3.80 Mn |
| Mar 31, 2023 | -1.22 Mn |
| Dec 31, 2022 | -1.41 Mn |
| Sep 30, 2022 | -3.34 Mn |
| Jun 30, 2022 | -2.59 Mn |
| Mar 31, 2022 | -3.44 Mn |
| Dec 31, 2021 | -4.62 Mn |
| Sep 30, 2021 | -4.58 Mn |